Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
1. autor: | Akter, Anika |
---|---|
Kolejni autorzy: | Alam, Marzia |
Format: | Praca dyplomowa |
Język: | English |
Wydane: |
Brac University
2022
|
Hasła przedmiotowe: | |
Dostęp online: | http://hdl.handle.net/10361/17039 |
Podobne zapisy
-
Biologics and Biosimilars as Treatment Options for Psoriasis
od: Moya, Amena Khatun
Wydane: (2023) -
Importance of biologics in rheumatoid arthritis management
od: Riyadh, S. M.
Wydane: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
od: Afroza, Halima
Wydane: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
od: Mehreen, Elnaj
Wydane: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
od: Islam, Nahidul
Wydane: (2023)